Cited 0 times in
Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김흥동 | - |
dc.contributor.author | 은호선 | - |
dc.contributor.author | 이영목 | - |
dc.contributor.author | 이준수 | - |
dc.contributor.author | 강훈철 | - |
dc.contributor.author | 권은지 | - |
dc.contributor.author | 김신혜 | - |
dc.date.accessioned | 2014-12-19T17:40:03Z | - |
dc.date.available | 2014-12-19T17:40:03Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1059-1311 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/91843 | - |
dc.description.abstract | PURPOSE: To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). METHODS: The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a 12-week maintenance phase with a target dose of 20-40 mg/kg rufinamide, adjusted according to its effectiveness and tolerability after a baseline period of 4 weeks. The primary outcome was measured by the seizure-reduction rate according to individual seizure type over the 12-week maintenance period. RESULTS: One hundred and twenty-eight patients with LGS who were determined to be unresponsive to one or more antiepileptic drugs or dietary therapy were enrolled. Of the 128 patients enrolled, 112 (87.5%) completed the study. After add-on rufinamide treatment, 46 patients (35.9%) achieved a more than 50% reduction in seizure frequency and 10 (7.8%) patients became seizure-free. When we identified those who responded with an at least 50% reduction in seizure frequency, 39.4% of the responders reported reductions in convulsive seizures, 36.4% in drop attacks, 33.3% in myoclonic seizures, and 20.0% in epileptic spasms. Overall, 32.8% of patients reported adverse effects, which were mostly mild and transient in nature. The most common adverse effects were fatigue (15 patients, 11.7%) and poor appetite (9 patients, 7.0%). Twenty-one (16.4%) patients experienced an increased seizure frequency. CONCLUSIONS: Rufinamide appears to be a safe and effective adjuvant treatment for many cases of intractable LGS. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adolescent | - |
dc.subject.MESH | Anticonvulsants/administration & dosage* | - |
dc.subject.MESH | Child | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Infant | - |
dc.subject.MESH | Intellectual Disability/drug therapy* | - |
dc.subject.MESH | Lennox Gastaut Syndrome | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Spasms, Infantile/drug therapy* | - |
dc.subject.MESH | Triazoles/administration & dosage* | - |
dc.title | Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학) | - |
dc.contributor.googleauthor | Shin Hye Kim | - |
dc.contributor.googleauthor | So-Hee Eun | - |
dc.contributor.googleauthor | Hoon-Chul Kang | - |
dc.contributor.googleauthor | Eun Ji Kwon | - |
dc.contributor.googleauthor | Jung Hye Byeon | - |
dc.contributor.googleauthor | Young-Mock Lee | - |
dc.contributor.googleauthor | Joon Soo Lee | - |
dc.contributor.googleauthor | Baik-Lin Eun | - |
dc.contributor.googleauthor | Heung Dong Kim | - |
dc.identifier.doi | 22421185 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01208 | - |
dc.contributor.localId | A02635 | - |
dc.contributor.localId | A02955 | - |
dc.contributor.localId | A03177 | - |
dc.contributor.localId | A00102 | - |
dc.contributor.localId | A00242 | - |
dc.contributor.localId | A00677 | - |
dc.relation.journalcode | J02648 | - |
dc.identifier.eissn | 1532-2688 | - |
dc.identifier.pmid | 22421185 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S1059131112000453 | - |
dc.subject.keyword | Rufinamide | - |
dc.subject.keyword | Lennox-Gastaut syndrome | - |
dc.subject.keyword | Child | - |
dc.contributor.alternativeName | Kim, Heung Dong | - |
dc.contributor.alternativeName | Eun, Ho Seon | - |
dc.contributor.alternativeName | Lee, Young Mock | - |
dc.contributor.alternativeName | Lee, Joon Soo | - |
dc.contributor.alternativeName | Kang, Hoon Chul | - |
dc.contributor.alternativeName | Kwon, Eun Ji | - |
dc.contributor.alternativeName | Kim, Shin Hye | - |
dc.contributor.affiliatedAuthor | Kim, Heung Dong | - |
dc.contributor.affiliatedAuthor | Eun, Ho Seon | - |
dc.contributor.affiliatedAuthor | Lee, Young Mock | - |
dc.contributor.affiliatedAuthor | Lee, Joon Soo | - |
dc.contributor.affiliatedAuthor | Kang, Hoon Chul | - |
dc.contributor.affiliatedAuthor | Kwon, Eun Ji | - |
dc.contributor.affiliatedAuthor | Kim, Shin Hye | - |
dc.citation.volume | 21 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 288 | - |
dc.citation.endPage | 291 | - |
dc.identifier.bibliographicCitation | SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, Vol.21(4) : 288-291, 2012 | - |
dc.identifier.rimsid | 29952 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.